Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 678 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR FDA Approves Second CAR T-Cell Therapy for Lymphoma May 22, 2018 ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... July 21, 2025 Colposcopia: Cómo prepararse y qué saber August 6, 2020 New Vaccine Stimulates Survivors’ Immune Systems to Keep Triple-Negative Cancer from... February 14, 2020 Load more HOT NEWS Looking to Help Rebuild Strength After Breast Cancer Treatment? Soccer May... For Women With Dense Breasts, An MRI May Be A Better... Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... EMA Recommends Extension of Indications for Selumetinib
